-
Mashup Score: 35The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout - 2 month(s) ago
Nature Reviews Rheumatology – Gout is associated with various cardiometabolic–renal comorbidities that increase the risk of mortality. Sodium–glucose cotransporter type 2 (SGLT2)…
Source: www.nature.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
Patients with higher baseline serum urate levels demonstrate increased recurrent gout hospitalization rates and subsequent risk for flare over 10 years of follow-up, according to data published in JAMA. The findings suggest that most gout flares are “potentially preventable at the population level” with the achievement of serum urate targets of less than 6 or 5 mg/dL, Hyon K. Choi,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Clinical Quiz: ACR Guideline for the Management of Gout - 2 month(s) ago
Test your knowledge of the ACR’s guideline for the management of gout with this quiz!
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Gout flare severity, recurrence risk not impacted by timing of urate lowering therapy - 2 month(s) ago
Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis. “Despite being a well-established therapy for gout, the timing of ULT initiation in relation to a gout flare remains debated,” Vicky Tai, MBChB, of the University of Auckland, in
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Urate-lowering therapy and dosing regimen impact the risk of gout flares, with greater fixed dosing linked to a greater risk of flares and prophylaxis associated with reductions in flare risk.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Urate-lowering therapy and dosing regimen impact the risk of gout flares, with greater fixed dosing linked to a greater risk of flares and prophylaxis associated with reductions in flare risk.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Cardiovascular Disease Hospitalizations: Spotlighting Disparities by Race in Rheumatic Disease - 3 month(s) ago
These data contribute to existing research into links observed between rheumatic diseases such as gout and cardiovascular disease among Indigenous North American populations.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Exposure to BPA, BPA Alternatives Could Increase Risk of Hyperuricemia, Gout in Women - 3 month(s) ago
A recent study points to a link between bisphenol exposure and elevated uric acid levels, with implications for gout risk, especially in women.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Baseline Serum Urate Linked to Gout Flare, Hospitalization - 3 month(s) ago
Higher serum urate levels at baseline were linked to higher rates of recurrent gout.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
Research on SGLT2 inhibitors in #gout is needed. They have been shown to reduce uric acid & gout flares, and may be uricosuric or be antiinflammatory. Also decreased incident gout (by half) among at-risk patients with type 2 diabetes (HR 0.54) https://t.co/ZEmhwqyDOv https://t.co/58YKD6pFyt